BRPI0717246A2 - Método para gerar anticorpos ativos contra um antígeno de resistência, anticorpos obtidos pelo dito método e seus usos - Google Patents

Método para gerar anticorpos ativos contra um antígeno de resistência, anticorpos obtidos pelo dito método e seus usos Download PDF

Info

Publication number
BRPI0717246A2
BRPI0717246A2 BRPI0717246-0A2A BRPI0717246A BRPI0717246A2 BR PI0717246 A2 BRPI0717246 A2 BR PI0717246A2 BR PI0717246 A BRPI0717246 A BR PI0717246A BR PI0717246 A2 BRPI0717246 A2 BR PI0717246A2
Authority
BR
Brazil
Prior art keywords
antibody
tumor
antibodies
sequences
seq
Prior art date
Application number
BRPI0717246-0A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Liliane Goetsch
Alexandra Jouhanneaud
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BRPI0717246A2 publication Critical patent/BRPI0717246A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0717246-0A2A 2006-09-28 2007-09-27 Método para gerar anticorpos ativos contra um antígeno de resistência, anticorpos obtidos pelo dito método e seus usos BRPI0717246A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0608514A FR2906533B1 (fr) 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
FR0608514 2006-09-28
PCT/EP2007/060243 WO2008046724A1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Publications (1)

Publication Number Publication Date
BRPI0717246A2 true BRPI0717246A2 (pt) 2013-10-08

Family

ID=38164542

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717246-0A2A BRPI0717246A2 (pt) 2006-09-28 2007-09-27 Método para gerar anticorpos ativos contra um antígeno de resistência, anticorpos obtidos pelo dito método e seus usos

Country Status (21)

Country Link
US (2) US8241646B2 (https=)
EP (4) EP2497491B1 (https=)
JP (1) JP5774276B2 (https=)
KR (1) KR101504770B1 (https=)
CN (1) CN101516394B (https=)
AR (1) AR063061A1 (https=)
AU (1) AU2007312437C1 (https=)
BR (1) BRPI0717246A2 (https=)
CA (1) CA2663561A1 (https=)
FR (1) FR2906533B1 (https=)
IL (1) IL197790A (https=)
MA (1) MA30954B1 (https=)
MX (1) MX2009003245A (https=)
NO (1) NO20091613L (https=)
NZ (1) NZ576420A (https=)
RU (1) RU2515904C2 (https=)
TN (1) TN2009000102A1 (https=)
TW (1) TWI516276B (https=)
UA (1) UA102812C2 (https=)
WO (1) WO2008046724A1 (https=)
ZA (1) ZA200902697B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011004899A1 (en) * 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
US20120282211A1 (en) * 2009-11-24 2012-11-08 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
EP2635602B1 (en) 2010-11-03 2016-09-07 Argen-X Nv Anti c-met antibodies
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
TW201613615A (en) 2014-06-30 2016-04-16 Academia Sinica Antagonists for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B for cancer therapy
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
AR105553A1 (es) * 2015-04-27 2017-10-18 Pf Medicament Anticuerpo del receptor del factor 1 del crecimiento similar a insulina (igf-1r) y su utilización para diagnosticar cáncer
TWI740824B (zh) * 2015-04-27 2021-10-01 法商皮爾法伯製藥公司 新穎的ｉｇｆ－１ｒ抗體及其用於癌症診斷之用途（一）
EP3334757A4 (en) * 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-Tigit ANTIBODY
US10981991B2 (en) * 2015-09-29 2021-04-20 Shanghai Zhangjiang Biotechnology Co., Ltd. PD-1 antibodies and uses thereof
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6261596A (ja) * 1985-09-11 1987-03-18 Japan Found Cancer Res 薬剤耐性癌に関するモノクロ−ナル抗体およびその製造
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
KR950700061A (ko) * 1992-02-06 1995-01-16 스티븐 엘. 네스비트 테트라아릴에틸렌에 의한 다중 약물 내성의 역전(reversal of multi -drug resistance by tetraarylethylenes)
IT1257893B (it) * 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5503984A (en) * 1993-04-13 1996-04-02 Health Research, Inc. Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein
WO1999066027A1 (en) * 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
DE60312639T2 (de) 2002-01-18 2007-11-29 Pierre Fabre Médicament Antikörper gegen igf-ir und ihre verwendungen
US20040121965A1 (en) 2002-09-20 2004-06-24 Wyeth Holdings Corporation Method of treating resistant tumors
WO2005035721A2 (en) * 2003-10-08 2005-04-21 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
WO2005077385A2 (en) 2004-02-18 2005-08-25 Gpc Biotech Ag Methods for treating resistant or refractory tumors
EP1742060A1 (en) * 2005-01-24 2007-01-10 DIGILAB BioVisioN GmbH TIF1-beta peptides and nucleic acids for diagnosis and therapy of cancer and colorectal cancerous disorders.

Also Published As

Publication number Publication date
ZA200902697B (en) 2010-04-28
US8808667B2 (en) 2014-08-19
CN101516394B (zh) 2014-07-30
WO2008046724A1 (en) 2008-04-24
EP2491945B1 (en) 2016-12-07
NO20091613L (no) 2009-06-26
CA2663561A1 (en) 2008-04-24
TN2009000102A1 (en) 2010-08-19
AR063061A1 (es) 2008-12-23
EP2497491B1 (en) 2017-03-01
US20100146650A1 (en) 2010-06-10
EP2491945A1 (en) 2012-08-29
UA102812C2 (ru) 2013-08-27
KR101504770B1 (ko) 2015-03-20
TW200822934A (en) 2008-06-01
MX2009003245A (es) 2009-07-07
NZ576420A (en) 2012-05-25
JP5774276B2 (ja) 2015-09-09
EP2494984B1 (en) 2017-01-04
FR2906533A1 (fr) 2008-04-04
AU2007312437B2 (en) 2014-01-23
RU2009114682A (ru) 2010-11-20
EP2497491A1 (en) 2012-09-12
MA30954B1 (fr) 2009-12-01
IL197790A (en) 2016-10-31
AU2007312437C1 (en) 2014-04-10
EP2491945B9 (en) 2017-03-08
HK1131063A1 (en) 2010-01-15
US20130028835A1 (en) 2013-01-31
KR20090057469A (ko) 2009-06-05
JP2010504743A (ja) 2010-02-18
EP2081592A1 (en) 2009-07-29
RU2515904C2 (ru) 2014-05-20
TWI516276B (zh) 2016-01-11
FR2906533B1 (fr) 2013-02-22
EP2081592B1 (en) 2016-01-13
EP2494984A1 (en) 2012-09-05
US8241646B2 (en) 2012-08-14
AU2007312437A1 (en) 2008-04-24
IL197790A0 (en) 2011-08-01
CN101516394A (zh) 2009-08-26

Similar Documents

Publication Publication Date Title
BRPI0717246A2 (pt) Método para gerar anticorpos ativos contra um antígeno de resistência, anticorpos obtidos pelo dito método e seus usos
CN102834113B (zh) 癌的治疗和/或预防用药物组合物
RU2641260C2 (ru) Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
CN101535344B (zh) 新型抗增殖抗体
CN102822335B (zh) 癌的治疗和/或预防用药物组合物
CN113286634A (zh) 对gucy2c特异性的抗体及其用途
KR20260046131A (ko) 이중특이적 항-PSMA x 항-CD28 항체를 이용한 전이성 거세-저항성 전립선암의 치료 방법
HK40060091A (en) Antibodies specific for gucy2c and uses thereof
HK1132752B (en) Novel antiproliferation antibodies

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2481 DE 24-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.